Key facts
- This page summarizes Patrick Verta's Form 4 filing for InspireMD, Inc. (NSPR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2025, 16:30.
Patrick Verta - 07 Jan 2025 Form 4 Insider Report for InspireMD, Inc. (NSPR)
- Reporting relationship
- EVP Clinical/Medical Affairs
- Issuer ticker
- NSPR
- Reported as of
- 07 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2025, 16:30:23 UTC
- Prior SEC filing
- 25 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patirck Verta
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick Verta filed Form 4 for InspireMD, Inc. (NSPR) on 10 Jan 2025.
Change
- Previous filing in this sequence was filed on 25 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NSPR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +83,072
- Change %
- +36%
- Price
- $0.000000
- Shares after
- 311,532
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NSPR
transaction
Derivative
Options to purchase common stock (right to buy)
Award
- Transaction value
- $0
- Shares
- +37,933
- Change %
- +48%
- Price
- $0.000000
- Shares after
- 117,281
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,933
- Exercise price
- $2.71
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 7, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service.
Footnote F2
The options vest and become exercisable in three equal installments, with 1/3 vesting on each of January 7, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service.